终止重组，新诺威一度跌超16%，最新回应！

Core Viewpoint - New Nuo Wei (300765.SZ) experienced a significant stock price drop following the announcement of the termination of its planned acquisition of 100% equity in Shiyao Baike, which was intended to be financed through a combination of share issuance and cash payment [1][2] Group 1: Company Announcement - On April 28, New Nuo Wei announced the termination of its restructuring plan due to changes in the pharmaceutical industry and capital market conditions since the initial planning [1] - The company had originally planned to acquire Shiyao Baike for a total consideration of 68.4 billion yuan in shares and 7.6 billion yuan in cash [1][2] Group 2: Financial Performance - In the first quarter of 2025, New Nuo Wei reported a revenue of 472 million yuan, representing a year-on-year decrease of 9.94%, and a net loss attributable to shareholders of 26.9 million yuan [3] Group 3: Market Context - The termination of the acquisition may be linked to the anticipated decline in sales of Shiyao Baike's main product, Jinyouli, due to its inclusion in inter-provincial alliance procurement [2] - Despite the recent stock price drop, the innovative pharmaceutical sector has shown strength, with New Nuo Wei's stock reaching a historical high on April 22 [2]